News

An international team has learned how the body activates a protein responsible for limiting muscle growth, a finding that could lead to therapies to improve ALS patients’ muscle function. The protein, called GDF8 or myostatin, determines both the number of muscle fibers the body produces and the fibers’ size. Researchers’…

Amyotrophic lateral sclerosis (ALS) patients experiencing feelings of apathy reported lower quality of life (QoL), particularly regarding achievements in life and community connectedness, a new Australian study reports. The research, “Apathy and its impact on patient outcome in amyotrophic lateral sclerosis,” appeared in the Journal of…

A naturally occurring enzyme improves ALS symptoms in mice and could lead to effective therapies in humans, a study suggests. The research, “Deletion of NAMPT in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death,” appeared in the journal Cell Reports. Data from…

A new model for predicting ALS patients’ survival looks promising, University of Michigan researchers report. In fact, it want a competition for models that can forecast survival. A combination of patients’ ability to walk, breathe and eat, plus their scores on a physical functioning scale and a lung function measure…

A protein called neuronal apoptosis inhibitor protein (NAIP) is a potential disease marker and predictor of outcomes in amyotrophic lateral sclerosis (ALS), according to a new study. The protein’s levels in ALS patients and controls were measured in blood samples in the study. The…

A dissolving tablet version of riluzole called BHV-0223 has shown positive bioequivalence when compared to the oral form of the therapy, Rilutek, developer Biohaven Pharmaceuticals announced. The dissolving tablet, placed under the tongue, is easier to administrate to patients with amyotrophic lateral sclerosis (ALS) who have trouble swallowing. BHV-0223 also was found…